Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


8th World Nephrology Conference

Sao Paulo, Brazil

Bruna Cristina Cardoso Martins

Bruna Cristina Cardoso Martins

Federal University of Ceara, Brazil

Title: Analysis of combination plasmapheresis, immunoglobulin and Rituximab in the treatment of antibody mediated rejection in after kidney transplantation: a review in literature


Biography: Bruna Cristina Cardoso Martins


Antibody-mediated rejection (AMR) is one of the important complications of renal transplant that results in the loss of the kidney graft when not treated. The Ministry of Health of the Brazil recommends the use of immunoglobulin (IVIg) or a combination of plasmapheresis (PP) for treatment. The aim of the study was to identify and describe the results of use of PF, IVIg and RIT in the treatment of AMR in after kidney transplantation in the literature. This is an integrative literature review using the key words: "rituximab", plasmaphereses", "immunoglobulin", "antibody-mediated rejection" and "kidney transplantation" in the databases PubMed, LILACS and Cochrane. Inclusion criteria were studies published between 2005 and 2015, follow-up type with clinical outcome analysis and combination of PP therapy and/or IVIG and/or RIT. The study included six papers, after analysis of 490 articles found. The mean duration of follow-up was 3.8 ± 1.9 years (min: 1, max: 6) and the number of monitored patients was on average 19.3 ± 18.0 (min:7, max:54). The studies analyzed that combined PP, IVIg and RIT, it was evaluated that there was articles in which the graft survival rate was 50% after 10 months of treatment, 71.4% at 1 year and 90% at the end of follow-up two years. In conclusion, the combination of PP, IVIg and RIT is protocol for the treatment of AMR in different transplant centers and were no differences between graft survival rates in relation to follow-up and early treatment, requiring the completion of prospective studies with longer follow-up.